Download PDF
Tierarztl Prax Ausg K Kleintiere Heimtiere 2022; 50(03): 225-231
DOI: 10.1055/a-1844-8554
Kasuistik

Erfolgreiche lokale Behandlung eines digitalen kaninen Mastzelltumors mit Tigilanoltiglat

Successful local treatment of a digital canine mast cell tumour with Tigilanol Tiglate
Karin Gasser
1   Tierklinik Schwarzmann Rankweil OG, Rankweil, Österreich
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die chirurgische Entfernung ist derzeit die Standardtherapie für resezierbare, nicht-metastasierte Mastzelltumoren (MZT). Seit kurzem steht mit dem intratumoral angewendeten Tigilanoltiglat eine neue Therapieoption für ausgewählte kutane und subkutane MZT zur Verfügung. Hier wird die erfolgreiche Behandlung eines 0,445 cm3 großen subkutanen MZTs an der Zehe eines American Staffordshire Terriers dokumentiert. Die daraus resultierende Wunde heilte komplikationslos innerhalb von 4 Wochen vollständig ab, und der Hund zeigte 8 Monate nach Therapie kein Rezidiv. Dank des neuen Medikaments konnte die Zehe erhalten werden, während chirurgisch eine vollständige Entfernung des Tumors nur mittels Amputation der Zehe möglich gewesen wäre.

Abstract

Surgical excision is currently the recommended treatment for resectable, nonmetastatic mast cell tumours. Recently, Tigilanol tiglate has become available as a novel intratumoral treatment modality for a subset of cutaneous and subcutaneous mast cell tumours. In the presented case, we document the successful treatment of a 0.445 cm3 subcutaneous digital mast cell tumour in an American Staffordshire Terrier. The resulting wound healed completely and without complications within 4 weeks and the dog was recurrence-free 8 months after treatment. Due to this new intratumoral treatment it was possible to preserve the digit, while a complete surgical resection of the tumour would have required digital amputation.

Schlüsselwörter

Therapie - Stelfonta - subkutaner Mastzelltumor - intratumoral - Hund - Staffordshire Terrier - Tumor

Key words

Therapy - Stelfonta - subcutaneous mast cell tumour - intratumoral - dog - Staffordshire Terrier

Zusatzmaterial



Publication History

Received: 10 May 2021

Accepted: 30 September 2021

Article published online:
05 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 London CA, Thamm DH. 21 – Mast Cell Tumors. In: Vail DM, Thamm DH, Liptak JM. Hrsg. Withrow and MacEwen’s Small Animal Clinical Oncology (Sixth Edition). St. Louis (MO): W. B. Saunders; 2019: 382-403
    CrossrefSearch in Google Scholar
  • 2 Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984; 21: 469-474
    CrossrefPubMedSearch in Google Scholar
  • 3 Kiupel M, Webster JD, Bailey KL. et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 2011; 48: 147-155
    CrossrefPubMedSearch in Google Scholar
  • 4 Thompson JJ, Pearl DL, Yager JA. et al. Canine subcutaneous mast cell tumor: characterization and prognostic indices. Vet Pathol 2011; 48: 156-168
    CrossrefPubMedSearch in Google Scholar
  • 5 Thompson JJ, Yager JA, Best SJ. et al. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Vet Pathol 2011; 48: 169-181
    CrossrefPubMedSearch in Google Scholar
  • 6 Boyle GM, D’Souza MMA, Pierce CJ. et al. Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models. PLOS ONE 2014; 9: e108887
    CrossrefPubMedSearch in Google Scholar
  • 7 Miller J, Campbell J, Blum A. et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Front Vet Sci 2019; 6: 106
    CrossrefPubMedSearch in Google Scholar
  • 8 De Ridder TR, Campbell JE, Burke-Schwarz C. et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). Journal of Veterinary Internal Medicine 2021; 35: 415-429
    CrossrefPubMedSearch in Google Scholar
  • 9 Stelfonta Epar Produktinformation. Im Internet:. Accessed March 25, 2021 at: https://www.ema.europa.eu/en/documents/product-information/stelfonta-epar-product-information_de.pdf
    PubMed
  • 10 Reddell P, Ridder TRD, Morton JM. et al. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. Journal of Veterinary Internal Medicine 2021; 35: 430-441
    CrossrefPubMedSearch in Google Scholar
  • 11 Scarpa F, Sabattini S, Bettini G. Cytological grading of canine cutaneous mast cell tumours. Veterinary and Comparative Oncology 2016; 14: 245-251
    CrossrefPubMedSearch in Google Scholar
  • 12 Keyerleber MA, Ferrer L. Effect of prophylactic cefalexin treatment on the development of bacterial infection in acute radiation-induced dermatitis in dogs: a blinded randomized controlled prospective clinical trial. Veterinary Dermatology 2018; 29: 37-e18
    CrossrefPubMedSearch in Google Scholar
  • 13 Jones PD, Campbell JE, Brown G. et al. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate. Journal of Veterinary Internal Medicine 2021; 35: 451-455
    CrossrefPubMedSearch in Google Scholar